Načítá se...
Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles
The Adeno-associated virus (AAV) gene delivery system is ushering in a new and exciting era in the United States; following the first approved gene therapy (Glybera) in Europe, the FDA has approved a second therapy, Luxturna [1]. However, challenges to this system remain. In viral gene therapy, the...
Uloženo v:
| Vydáno v: | PLoS Pathog |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5933702/ https://ncbi.nlm.nih.gov/pubmed/29723270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.ppat.1006929 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|